DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
Completed
Conditions studied: Breast Cancer
In brief
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to systemic therapy. PURPOSE: This laboratory study is looking at DNA in predicting response after systemic therapy in women with metastatic breast cancer.
Key facts
- Study ID
- NCT00899548
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 182
- Starts
- 2007-01-01
- Expected to finish
- 2016-10-01
- Last updated by the study team
- 2019-07-26
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: accepted.
Where it is running
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.